Warfarin. Ciprofloxacin, The serum concentration of Warfarin can be increased when it is combined with Ciprofloxacin. Cisapride, The metabolism of Warfarin
The metabolism of Azithromycin can be decreased when combined with Methimazole. Ciprofloxacin, Ciprofloxacin may decrease the excretion rate of
500 mg, 750 mg Ciprofloxacin as Ciprofloxacin side effects may be observed due to inhibition of their metabolic clearance by ciprofloxacin.
Metabolism of ceftriaxone is negligible. Route of elimination Ciprofloxacin, Ceftriaxone may decrease the excretion rate of Ciprofloxacin
ciprofloxacin will increase the level or effect of ramelteon by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Ciprofloxacin may decrease the metabolism of ramelteon; if ciprofloxacin is coadministered with ramelteon, monitor the patient closely for toxicity. ranolazine. ciprofloxacin and ranolazine both increase QTc interval.
ciprofloxacin increases ciprofloxacin Non-renal clearance of ciprofloxacin is mainly due to active trans-intestinal secretion and metabolism.
ciprofloxacin will increase the level or effect of ramelteon by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Ciprofloxacin may decrease the metabolism of ramelteon; if ciprofloxacin is coadministered with ramelteon, monitor the patient closely for toxicity. ranolazine. ciprofloxacin and ranolazine both increase QTc interval.
Metabolism: Ciprofloxacin is an inhibitor of human cytochrome P450 1A2 (CYP1A2). Co-administration of ciprofloxacin with other drugs metabolized by CYP1A2 results in increased plasma concentrations of these drugs and could lead to toxicity.
together account for approximately 10% of the intrav enous dose. The binding of ciprofloxacin to serum proteins is 20 to 40%. Ciprofloxacin is an inhibitor of human cytochrome P450 1A2 (CYP1A2) mediated metabolism. Coadministration of ciprofloxacin with other drugs primarily metabolized by
[email protected]